Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304796 | 0.87 | L3MBTL1 (0.55) | SMN1; SMN2L3MBTL1TDP1KEAP1ALDH1A1 | |
| SCHEMBL6400651 | 0.86 | F2RL1 (0.47) | TDP1ALDH1A1MAPTHDAC2HDAC8 | |
| SCHEMBL20897266 | 0.85 | KEAP1 (0.55) | L3MBTL1TDP1KEAP1MMP12ALDH1A1 | |
| SCHEMBL20897233 | 0.85 | MAPT (0.50) | TDP1ALDH1A1FFAR1MAPT | |
| SCHEMBL1149507 | 0.85 | PLAAT3 (0.52) | SMN1; SMN2TDP1ALDH1A1FFAR1MAPT | |
| SCHEMBL1738091 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL1TDP1ALDH1A1MAPT | |
| Alcohol SCHEMBL28404120 | 0.84 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1TDP1KEAP1ALDH1A1 | |
| SCHEMBL717900 | 0.84 | TDP1 (0.56) | SMN1; SMN2L3MBTL1TDP1KEAP1MMP12 | |
| SCHEMBL3600889 | 0.84 | F2RL1 (0.69) | SMN1; SMN2L3MBTL1ALDH1A1FFAR1MAPT | |
| SCHEMBL20897258 | 0.83 | FFAR1 (0.49) | SMN1; SMN2ALDH1A1FFAR1MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | SMN1; SMN2 4646/4885L3MBTL1 726/4885TDP1 2685/4885 |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | SMN1; SMN2 640/4885L3MBTL1 398/4885TDP1 2521/4885 |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | DDO, DAO, SRR | SMN1; SMN2 640/4885L3MBTL1 398/4885TDP1 2521/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | SMN1; SMN2 4646/4885L3MBTL1 726/4885TDP1 2685/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | SMN1; SMN2 4646/4885L3MBTL1 726/4885TDP1 2685/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | SMN1; SMN2 4710/4885L3MBTL1 2631/4885TDP1 4623/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | SMN1; SMN2 4646/4885L3MBTL1 726/4885TDP1 2685/4885 |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | SMN1; SMN2 640/4885L3MBTL1 398/4885TDP1 2521/4885 |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | SMN1; SMN2 4646/4885L3MBTL1 726/4885TDP1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.